AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06036511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: This is a single arm, open-label, prospective cohort clinical trial.~No blinding is required for this trial.~A total of 14 adult patients with PTSD will be recruited from UNM outpatient clinics and undergo rsfMRI and behavioral assessment prior to ketamine treatment. They will complete baseline scan at day one, a preparatory session (initial part of KAP), IM ketamine treatment, then within 24 hours, an integration session to take advantage of neuroplasticity for optimal therapeutic progress. Each participant will have two complete KAP sessions (preparation, treatment, and integration) followed by rsfMRI within approximately 24 hours, and again approximately two weeks after the completion of the second KAP session. Patients will also have repeat clinical assessments after each treatment. Changes in PTSD symptoms will be correlated with changes in connectivity at each rsfMRI.
Study NCT05154721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental Group - Mila-Learn
Description: Eight tasks are used in Mila-Learn.
Study NCT05154721 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: control Group - Mila-Placebo
Description: Eight tasks similar to Mila-Learn are used in the placebo group
Study NCT05060627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: In phase 1:~* Dose level -1: Belantamab-Mafodotin 1.9 mg/kg day 1, Q8W~* Dose level 1,2,3: Belantamab-Mafodotin 2.5 mg/kg day 1, Q8W In phase 2: maximum tolerated dose (MTD) of the combination
Study NCT05060627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: In phase 1:~* Dose level -1, 1: Carfilzomib 20/45 mg/m2 days 1, 8, and 15, Q4W.~* Dose level 2: Carfilzomib 20/56 mg/m2 on days 1, 8, and 15, Q4W~* Dose level 3: Carfilzomib 20/70 mg/m2 on days 1, 8, and 15, Q4W.~In phase 2: maximum tolerated dose (MTD) of the combination
Study NCT05060627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Description: Dexamethasone 40 mg weekly (days 1, 8, 15 and 22) or 20 mg in patients > 75 years old., Q4W
Study NCT05911607 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low power laser
Description: Phototherapy for extraction sockets using two different lasers.
Study NCT06545253 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: microRNAs analysis
Description: Patients will undergo routinary ophthalmological examination, multimodal retinal imaging and blood sampling
Study NCT05130892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 1 tablet (0.5mg) / time, once a day
Study NCT05130892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast
Description: 1 capsule (0.1g) / time, 3 times a day
Study NCT05130892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oridonin
Description: 2 tablets (0.5g) / time, 3 times a day;
Study NCT05404035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Connections for relatives of people with eating disorders and personality disorders
Description: The FC program (Fruzzetti and Hoffman, 2005) is divided into 7 modules:~1. Introduction to the intervention program. Program objectives, guidelines, criteria, and symptoms of ED and PD.~2. Psychoeducation on the development of ED and PD, explanatory theories, available treatments, comorbidity with PD.~3. Emotional regulation skills and awareness, and to decrease emotional reactivity.~4. Skills to improve the quality of relationships in family interactions (letting go of guilt and anger, acceptance skills in relationships).~5. Communication skills and effective self-expression, such as validation.~6. Problem management and making safe plans for crisis management.~7. Making new sense of my relationship with my family member, an opportunity to grow together.~All the modules include practice exercises, video viewing, and homework assignment.
Study NCT05404035 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Treatment As Usual
Description: Family members with this condition will continue to receive the usual treatment provided by their referral care center. In addition, we will optimize the treatment, following the recommendations of the international guidelines for the treatment of ED (NICE, 2017). There will be 3 two-hour session in group format each week, with the following components: Up-to-date information and research on ED and PD; Psychoeducation on the development of ED and PD; Explanatory theories; Available treatments and comorbidity.~In both conditions, after each face-to-face session, the participant will be asked to review the contents addressed during the session as homework (independently of the homework corresponding to the specific module being addressed). All interventions carried out with family members will be performed by clinical psychologists or general health psychologists with at least a master's degree or a doctoral degree and previous training in the application of the programs.
Study NCT05780541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07304814
Description: PF-07304814 is a phosphate ester prodrug of PF-00835231 (active moiety), a potent and selective inhibitor of the SARS-CoV-2 3CLpro.
Study NCT05780541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% sodium chloride solution
Study NCT05780541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Antiviral agent
Study NCT05780541 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Antiviral agent
Study NCT05505812 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS-IT101
Description: Adoptive transfer of 1x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
Study NCT05606393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality speech training
Description: virtual reality speech training that focuses on receptive and expressive aspects of language, through a newly developed interactive virtual reality software
Study NCT05606393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional speech therapy
Description: traditional speech therapy in current clinical use, that focuses on language comprehension, naming, fluency, repetition.
Study NCT05606393 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional speech therapy
Description: traditional speech therapy in current clinical use, that focuses on language comprehension, naming, fluency, repetition.
Study NCT05539820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki is based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distant Reiki, Reiki practitioners followed the traditional Usui Reiki protocol for distant healing. Reiki practitioners first undertake the name of students and then send the healing energy to the students.
Study NCT05337709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education intervention and medication review
Description: Education on osteoarthritis and pain management will be provided to the patients by face-to-face communication at the first meeting, aided with a leaflet, then patients will get the follow-up calls and a video will be shown to enforce the intervention. Medication review includes the assessment of patients' knowledge on the indication, identification of any drug-related problem, and counseling on the proper use of medication.
Study NCT03564548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPP001
Description: Group assigned to PPP001
Study NCT03564548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine sulfate or Hydromorphone or Oxycodone
Description: Group assigned to morphine sulfate or hydromorphone or oxycodone
Study NCT04786652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: estimated stroke volume variation (esSVV, Nihon Kohden, Japan)
Description: Assessment of the estimated stroke volume variation (esSVV, Nihon Kohden, Japan) in the early postoperative period after OPCAB
Study NCT04786652 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of fluid responsiveness in mechanically ventilated patients after OPCAB
Description: In mechanically ventilated patients after OPCAB within two hrs after intervention: passive leg raising (PLR), increased PEEP, and mini-fluid load (mFL) tests will be followed by standard fluid load (sFL). Monitoring: SVVPCA, PPVPCA, esSVV, HLI, PVI, pre-ejection fraction (PEP, echocardiography), CIPCA, esCI and CISTD. Transthoracic echocardiography will be performed to assess the volume of heart chambers, ejection fraction and pre-ejection phase (PEP).
Study NCT04786652 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of fluid responsiveness in spontaneously breathing patients at 18 hrs of the postoperative period
Description: 2) In spontaneously breathing patients at 18 hrs of the postoperative period: PLR, and mFL tests followed by sFL. Monitoring: SVVPCA, PPVPCA, esSVV, PVI, PEP, CIPCA, esCI and CISTD. Transthoracic echocardiography will be performed to assess the volume of heart chambers, ejection fraction and pre-ejection phase.
Study NCT04856345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking with music with synchronisation
Description: Walking with music than one can synch to
Study NCT04856345 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking with music without synchronisation
Description: Walking with music than one cannot synch to
Study NCT04856345 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: walking without music
Description: Walking without music
Study NCT04941664 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0.5% levobupivacaine
Description: This study adopts a Modified Narayana rule (MNR), a sequential up-and-down pharmacodynamics method (UDM) to estimate the minimum effective local anesthetic volume of 90% (MELVA90) of cases of the aforementioned local anesthetic (LA), in order to produce the surgical anesthesia of the patients scheduled for shoulder surgeries. Based on the principal investigator's clinical experience, the initial volume of 8ml will be used. Depending on the success or failure of the superior trunk block, which is defined as the readiness for surgery at 30 minutes after the block, the volume for the next patient will be adjusted up or down by 2ml. The upper dose limit of the study to minimize the potential for local anesthetic systemic toxicity will be 16ml and the lower dose limit will be 4ml, which will be of no clinical importance.
Study NCT06396468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: sevoflurane (1-1.2 MAC)
Study NCT06396468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: 100-400 mcg/kg /min of propofol
Study NCT06210269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: Oral antibiotic
Study NCT06210269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral placebo
Study NCT05783284 — intervention group
Intervention type: DEVICE
Intervention: Holocare Studio 2 (HS2)
Description: 3D HV
Study NCT05474248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Diaphragmatic Breathing Training
Study NCT06312371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
Study NCT06312371 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
Study NCT03947515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prostate biopsy
Description: All patients included, will report to the urology department on the date previously agreed with the surgeon. The patient will be seen by the nurse and urologist on duty as part of outpatient care or, more rarely, in ambulatory care. After verification of the patient's identity, the signature of informed consent, the absence of immediate contraindications to biopsy (haemorrhagic and infectious) and the patient's proper preparation (antibiotic prophylaxis and possible enema), the patient will be installed for the taking of samples covered by the protocol (rectal swabbing and prostate biopsies, see paragraph IX). If the patient has not taken the antibiotic prophylaxis or performed the enema, he or she will be reconvened at a later date for the biopsies. After the prostatic biopsies have been performed, the patient's participation in the study ends and his follow-up resumes according to the recommendations adapted to his pathology.
Study NCT03947515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urinary sampling
Description: It will be collected after the prostate massage performed by the surgeon in charge of the patient during his clinical examination for prostate cancer screening. After elimination of the first draft, the urine will be collected in 2 tubes with borated preservative
Study NCT03947515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rectal swabbing before biopsies are performed
Description: A rectal swab will then be taken by the urologist on the day the prostate biopsies are taken. The analysis of the digestive microbiota will eliminate contamination of prostate biopsies by bacteria from the faecal flora during transrectal sampling
Study NCT05364827 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CTCA
Description: CTCA performed in intervention arm patients prior to CTO PCI
Study NCT04971551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: Oral on an empty stomach
Study NCT06114732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking exercise behaviour change intervention + TENS
Description: MOSAIC: Participants in this group receive two 60-minute individual video telehealth consultations (on weeks one \& two) and two 20-minute follow-up telephone calls (weeks six \& 12) delivered at a convenient time over the internet. All sessions are delivered by a trained senior/band 6 physiotherapist. All participants randomized to this arm are provided with a pedometer and a patient manual which include information on intermittent claudication (IC), risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.~HF-TENS - TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin. Participants will be asked to use TENS during their everyday walking-based tasks, and any planned walking activity they undertake.
Study NCT04655599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorinab
Description: Olorinab tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
Study NCT04655599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olorinab
Description: Olorinab tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
Study NCT04655599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Olorinab matching placebo tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
Study NCT04655599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olorinab matching placebo tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
Study NCT05631626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTx-1301 - Dexmethylphenidate 25mg
Description: 25mg CTx-1301 (Dexmethylphenidate tablet)
Study NCT05631626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTx-1301 - Dexmethylphenidate 37.5mg
Description: 37.5mg CTx-1301 (Dexmethylphenidate tablet)
Study NCT05631626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTx-1301 - Dexmethylphenidate 50mg
Description: 50mg CTx-1301 (Dexmethylphenidate tablet)
Study NCT05631626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05028842 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: None.This is an observational study
Study NCT05137678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glibenclamide
Description: Glibenclamide was given orally or by nasal feeding
Study NCT04844840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: STP705 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA, respectively
Study NCT04844840 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT06545201 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RE001 T cell
Description: All subjects who met the entry and exit criteria and signed the informed consent form were observed in hospital at the beginning of lymphocyte clearance chemotherapy, with the dosage of cyclophosphamide (600-800mg/m\^2/days,-5,-4 days) and fludarabine (25-30mg/m\^2/days,-5,-4,-3 days), at least two days after the completion of lymphocyte clearance chemotherapy.
Study NCT05449977 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnose
Description: First, the participants will be asked to fill out a structured questionnaire containing their sociodemographic characteristics. Then, the 2-minute walk test, the International physical activity questionnaire, the SF-36 short form, and the World health organization quality of life questionnaire will be applied respectively.
Study NCT06545149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioNutri AR-1,
Description: intervention with fermented and nutritionally balanced food twice a day
Study NCT06545149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: BioNutri AR-1,
Description: intervention with fermented and nutritionally balanced food twice a day
Study NCT05527756 — intervention group
Intervention type: OTHER
Intervention: Scar Cosmesis Assessment and Rating (SCAR) scale
Description: The SCAR scale consists of two simple questions about symptoms (itch and pain) with yes/no response options that are responded to by the patient and six clinician-related items that are rated by observers through photos of the incisions. This scale includes both objective measurements and patient-reported symptoms
Study NCT05527756 — intervention group
Intervention type: OTHER
Intervention: Numerical rating scale (NRS)
Description: The NRS scale, in which the patients score the cosmetic appearance of the scar from 0 to 10, is questioned.
Study NCT06497387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRG-1801
Description: PRG-1801 (BCMA-targeting CAR-T Cells)
Study NCT06495658 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Participants will be asked to take a daily dose of prebiotic supplement for 8 weeks.
Study NCT06495658 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic
Description: Participants will be asked to take a daily dose of prebiotic supplement for 8 weeks.
Study NCT06303999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube
Description: The group was given enteral nutritional support with IOE according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
Study NCT06303999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube
Description: Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.